-$0.04 EPS Expected for Clearside Biomedical, Inc. (NASDAQ:CLSD) This Quarter

Posted by on Jun 9th, 2022

Wall Street brokerages expect Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) to report earnings per share (EPS) of ($0.04) for the current quarter, according to Zacks. Three analysts have issued estimates for Clearside Biomedical’s earnings, with estimates ranging from ($0.13) to $0.21. Clearside Biomedical reported earnings per share of ($0.11) during the same quarter last year, which suggests a positive year-over-year growth rate of 63.6%. The company is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Clearside Biomedical will report full year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.51) to $0.27. For the next financial year, analysts expect that the company will post earnings of ($0.44) per share, with EPS estimates ranging from ($0.54) to ($0.33). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD – Get Rating) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.10). Clearside Biomedical had a return on equity of 0.31% and a net margin of 0.28%. During the same quarter in the previous year, the firm earned ($0.13) earnings per share.

A number of analysts have recently issued reports on CLSD shares. StockNews.com started coverage on shares of Clearside Biomedical in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research cut shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Monday, May 2nd. TheStreet cut shares of Clearside Biomedical from a “c” rating to a “d+” rating in a research note on Wednesday, May 11th. Wedbush reaffirmed an “outperform” rating and set a $9.00 target price on shares of Clearside Biomedical in a research note on Friday, March 11th. Finally, JMP Securities cut their target price on shares of Clearside Biomedical from $11.00 to $10.00 and set a “market outperform” rating for the company in a research note on Friday, March 11th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Clearside Biomedical currently has an average rating of “Buy” and a consensus price target of $9.25.

Shares of NASDAQ CLSD opened at $1.39 on Thursday. The firm has a fifty day moving average price of $1.68 and a 200-day moving average price of $2.13. Clearside Biomedical has a 1 year low of $1.27 and a 1 year high of $7.73.

Large investors have recently modified their holdings of the business. Jump Financial LLC purchased a new position in shares of Clearside Biomedical in the 3rd quarter worth $229,000. Assenagon Asset Management S.A. grew its stake in shares of Clearside Biomedical by 8,559.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,634,412 shares of the company’s stock worth $4,495,000 after buying an additional 1,615,538 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Clearside Biomedical in the 3rd quarter worth $263,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Clearside Biomedical by 200.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 79,967 shares of the company’s stock worth $480,000 after acquiring an additional 53,311 shares during the last quarter. Finally, Caxton Associates LP lifted its holdings in shares of Clearside Biomedical by 169.8% in the 3rd quarter. Caxton Associates LP now owns 66,569 shares of the company’s stock worth $399,000 after acquiring an additional 41,892 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Clearside Biomedical Company Profile (Get Rating)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

Recommended Stories

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Want More Great Investing Ideas?

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.